Biomarkers · Chemical
Inhibin A
- Also listed as
- DIA Value
- Primary unit
- pg/mL
- LOINC codes
- 23883-2
- Tests that measure Inhibin A
- Labcorp 6, Quest Diagnostics 6
Ranges
Each lab publishes a reference range for the population groups it tests, usually the middle 95% of results. These intervals describe that population, not an optimal or healthy target. How ranges differ
Quest Diagnostics, Inhibin A 34472
| Population | Interval |
|---|---|
| Male | <2.0 pg/mL |
| Female | Not stated |
| Premenopausal | <98.0 pg/mL |
| Postmenopausal | <2.1 pg/mL |
Tests
Check the catalog code, specimen, method and preparation for every test that measures Inhibin A. Select up to five tests to compare them side by side.
Labcorp 6 tests
Single-analyte tests
Inhibin A, Ultrasensitive 146803
Serum · Fasting not stated · Turnaround 4 - 6 days
Labcorp catalog pageMethod and collection
- Method
- Immunochemiluminometric (ICMA)
- Collection
- Transfer the serum into a LabCorp PP transpak frozen purple tube with screw cap (LabCorp No 49482). Freeze immediately and maintain frozen until tested. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
- Reference notes
- • Male: <3.6 pg/mL • Female: − <4 months: <18.0 pg/mL − 4 months to 9 years: <5.0 pg/mL − 10 years: <5.0 pg/mL − 11 to 13 years: <160.0 pg/mL − 14 to 18 years: 10.0−249.0 pg/mL − Early follicular: <34.0 pg/mL − Late follicular: <99.0 pg/mL − Periovulatory: 8.0−233.0 pg/mL − Midluteal: <145.0 pg/mL − End luteal: <145.0 pg/mL − Postmenopausal: <4.0 pg/mL • Tanner stage: − I: <7.0 pg/mL − II: <14.0 pg/mL − III: <52.0 pg/mL − IV: <69.0 pg/mL − V: <126.0 pg/mL Inhibin A performed by Beckman Coulter Access Automated Immunoassay methodology. Values obtained with different assay methods or kits cannot be used interchangeably.
Panels that include this biomarker
α-Fetoprotein (AFP) Tetra Profile 017319
13 analytes · Serum · Fasting not stated · Turnaround 2 - 5 days
Labcorp catalog pageMethod and collection
- Method
- Chemiluminescent immunoassay
- Collection
- Collect in serum separator tube with gel barrier. Allow blood to clot, avoiding hemolysis. Separate serum from cells by centrifugation. Transport spun tube to testing laboratory. Pour-off is not advised. Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood.
First Trimester Screen With Nuchal Translucency 017500
15 analytes · Serum · Fasting not stated · Turnaround 2 - 5 days
Labcorp catalog pageMethod and collection
- Method
- Chemiluminescent immunoassay
- Collection
- Collect in serum separator tube with gel barrier. Allow blood to clot, avoiding hemolysis. Separate serum from cells by centrifugation. Transport spun tube to testing laboratory. Pour-off is not advised. Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood.
Serum Integrated 2 017270
16 analytes · Serum · Fasting not stated · Turnaround 2 - 5 days
Labcorp catalog pageMethod and collection
- Method
- Chemiluminescent immunoassay
- Collection
- Collect in serum separator tube with gel barrier. Allow blood to clot, avoiding hemolysis. Separate serum from cells by centrifugation. Transport spun tube to testing laboratory. Pour-off is not advised. Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood.
Integrated 2 017170
22 analytes · Serum · Fasting not stated · Turnaround 2 - 5 days
Labcorp catalog pageMethod and collection
- Method
- Chemiluminescent immunoassay
- Collection
- Collect in serum separator tube with gel barrier. Allow blood to clot, avoiding hemolysis. Separate serum from cells by centrifugation. Transport spun tube to testing laboratory. Pour-off is not advised. Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood.
Sequential 2 017750
22 analytes · Serum · Fasting not stated · Turnaround 2 - 5 days
Labcorp catalog pageMethod and collection
- Method
- Chemiluminescent immunoassay
- Collection
- Collect in serum separator tube with gel barrier. Allow blood to clot, avoiding hemolysis. Separate serum from cells by centrifugation. Transport spun tube to testing laboratory. Pour-off is not advised. Maternal serum specimens must be drawn prior to amniocentesis to avoid contamination with fetal blood.
Quest Diagnostics 6 tests
Single-analyte tests
Inhibin A 34472
Serum · Fasting not stated · Turnaround Set up: Mon-Fri; Report available: 9 days
Quest Diagnostics catalog pageMethod and collection
- Method
- Immunoassay (IA)
Panels that include this biomarker
Sequential Integrated Screen, Part 2 16133
4 analytes · Serum · Fasting not stated
Quest Diagnostics catalog pageMethod and collection
- Method
- Chemiluminescence (CL) • Immunoassay (IA)
- Collection
- Collect between 14.0 to 22 6/7 weeks. Maternal date of birth (mm/dd/yy), Estimated Date of Delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results. Must complete patient demographic information using the Maternal Serum Screen Requisition.
- Reference notes
- See Laboratory Report
Integrated Screen, Part 2 16150
5 analytes · Serum · Fasting not stated · Turnaround Set up: Mon-Fri (a.m.); Report available: Tues-Fri, Mon p.m.
Quest Diagnostics catalog pageMethod and collection
- Method
- Chemiluminescence (CL) • Immunoassay (IA)
- Collection
- For manual orders use "Maternal Serum Screen Requisition". The Integrated Screen, Part 2 should be performed 14.0 weeks to 22.9 weeks gestational age. A special maternal serum screen requisition designed to obtain patient data and the patient's informed consent must be utilized when ordering this test. Because these results are influenced by certain patient characteristics, all data requested on the requisition form must be complete: Patient's (maternal) date of birth, estimated date of delivery, weight, race, diabetic status (is patient insulin dependent; prior to pregnancy), number of fetuses, repeat sample and neural tube defect history must be provided for interpretation of results.
- Reference notes
- See Laboratory Report
Penta Screen 15934
5 analytes · Serum · Fasting not stated · Turnaround Set up: Tues-Sat
Quest Diagnostics catalog pageMethod and collection
- Method
- Immunoassay (IA)
- Collection
- For manual orders use "Maternal Serum Screen Requisition". The Penta Screen test in pregnant women should be performed between 14.0 and 22.9 weeks gestational age, although the optimal period is 15.0-16.9 weeks. This time frame allows sufficient opportunity for further diagnostic studies if the initial Penta Screen test results are abnormal. Specimens submitted before 14.0 weeks or after 22.9 weeks gestation cannot be properly evaluated for open neural tube defects, Down syndrome or Trisomy 18. The "Maternal Serum Screen Requisition" designed to obtain patient data and the patient's informed consent must be utilized when ordering the Penta Screen test. Because the Penta Screen test results are influenced by certain patient characteristics, the following data must be provided with the specimen in order to permit accurate interpretation of results: date of collection, patient's (maternal) date of birth, patient's estimated date of delivery, patient's weight, patient's race, patient's diabetic status (is patient insulin-dependent prior to pregnancy), number of fetuses, and whether this is a repeat sample.
- Reference notes
- See Laboratory Report
Serum Integrated Screen, Part 2 16167
6 analytes · Serum · Fasting not stated · Turnaround Set up: Mon-Fri (a.m.); Report available: Tues-Fri, Mon p.m.
Quest Diagnostics catalog pageMethod and collection
- Method
- Chemiluminescence (CL) • Immunoassay (IA)
- Collection
- Collect between 14.0 weeks to 22 6/7 weeks. Maternal date of birth (mm/dd/yy), estimated date of delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results. Must complete patient demographic information using the Maternal Serum Screen Requisition.
Stepwise, Part 2 16465
7 analytes · Serum · Fasting not stated · Turnaround Set up: Mon-Sat
Quest Diagnostics catalog pageMethod and collection
- Method
- Chemiluminescence (CL) • Immunoassay (IA)
- Collection
- Collect between 14.0 weeks to 22.9 weeks. Mother's date of birth (mm/dd/yy), Estimated Date of Delivery by US/LMP/PE, weight, race, insulin-dependent diabetes status, repeat sample (Y/N), number of fetuses, and neural tube defect history must be provided for interpretation of results. Must complete all patient demographic information using the appropriate questions from the entry fields in the regular requisition.
- Reference notes
- See Laboratory Report
0 of 5 tests selected
Pick one moreSources
6 tests: codes, specimens, methods, preparation and reference intervals.
Quest Diagnostics test catalog
6 tests: codes, specimens, methods, preparation and reference intervals.
LOINC 23883-2
Regenstrief Institute codes that identify the same result across labs.
Search ClinicalTrials.gov for Inhibin A
Registered studies that measure Inhibin A, on the U.S. National Library of Medicine registry.
Verify these ranges and sources
We compile this page from named laboratory catalogs, guidelines and studies. Labs calculate reference intervals from the people they test, for one assay method and one population group, so an interval describes that population rather than an optimal target.
Interpret your own results with a licensed clinician, or track your lab history and health goals in Aumnivida.
Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.